Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
NeuBase Therapeutics Inc (NBSE)
NASDAQ:NBSE
Holding NBSE?
Track your performance easily
NBSE Stock Chart & Stats
Day’s Range$0.37 - $0.39
52-Week Range― - ―
Previous Close$0.39
Volume97.74K
Average Volume (3M)N/A
Market Cap
$1.42M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
NeuBase Therapeutics News
PremiumCompany Announcements
NeuBase Therapeutics Plans Dissolution and Asset Liquidation
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NBSE FAQ
What was NeuBase Therapeutics Inc’s price range in the past 12 months?
Currently, no data Available
What is NeuBase Therapeutics Inc’s market cap?
Currently, no data Available
When is NeuBase Therapeutics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were NeuBase Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is NeuBase Therapeutics Inc overvalued?
According to Wall Street analysts NeuBase Therapeutics Inc’s price is currently Overvalued.
Does NeuBase Therapeutics Inc pay dividends?
NeuBase Therapeutics Inc does not currently pay dividends.
What is NeuBase Therapeutics Inc’s EPS estimate?
NeuBase Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NeuBase Therapeutics Inc have?
Currently, no data Available
What happened to NeuBase Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NeuBase Therapeutics Inc?
Among the largest hedge funds holding NeuBase Therapeutics Inc’s share is Greenlight Capital Inc. It holds NeuBase Therapeutics Inc’s shares valued at 61K.
---
Company Description
NeuBase Therapeutics Inc
NeuBase Therapeutics, Inc. engages in the development of drugs for patients with genetic neurological disorder. Its pipelines include Huntington's Disease, NT0100 Program - PATrOL Enabled gamma-PNA for Huntington's Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA.
---
NBSE Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---